Subcutaneous unfractionated heparin showed no clear difference in VTE‐related mortality at 3 months compared with low molecular weight heparin (low certainty).

1 finding from 1 review

Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism 2017 · Cochrane Headline outcomes only
OR 0.53 [0.17, 1.67]
8 studies · 2469 participants
Low

Subcutaneous unfractionated heparin vs unfractionated heparin

VTE‐related mortality4 · people aged ≥ 18 years with a diagnosis of new or recurrent VTE

Subcutaneous unfractionated heparin showed no clear difference in VTE‐related mortality at 3 months compared with intravenous unfractionated heparin (low certainty).

1 finding from 1 review

Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism 2017 · Cochrane Headline outcomes only
OR 0.98 [0.2, 4.88]
9 studies · 1168 participants
Low

Higher‐dose heparin vs standard‐dose heparin

VTE‐related mortality4 · people undergoing bariatric surgery

1 finding from 1 review

Pharmacological interventions for preventing venous thromboembolism in people undergoing bariatric surgery 2022 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 597 participants
Low

Subcutaneous unfractionated heparin vs low molecular weight heparin

All‐cause mortality (7 days ‐ 3 months) · people aged ≥ 18 years with a diagnosis of new or recurrent VTE

Subcutaneous unfractionated heparin showed no clear difference in all‐cause mortality (7 days ‐ 3 months) compared with low molecular weight heparin (low certainty).

1 finding from 1 review

Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism 2017 · Cochrane Headline outcomes only
OR 0.73 [0.5, 1.07]
7 studies · 2272 participants
Low

Subcutaneous unfractionated heparin vs unfractionated heparin

All‐cause mortality (5 days to 12 months) · people aged ≥ 18 years with a diagnosis of new or recurrent VTE

Subcutaneous unfractionated heparin showed no clear difference in all‐cause mortality (5 days to 12 months) compared with intravenous unfractionated heparin (low certainty).

1 finding from 1 review

Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism 2017 · Cochrane Headline outcomes only
OR 1.74 [0.67, 4.51]
8 studies · 972 participants
Low

Unfractionated heparin vs low molecular weight heparin

All cause mortality · people undergoing major amputation of the lower extremity

The review found no eligible studies for this question.

1 finding from 1 review

Primary prophylaxis for venous thromboembolism in people undergoing major amputation of the lower extremity 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Low molecular weight heparin vs placebo or no prophylaxis

Mortality due to other causes · prevention of venous thromboembolism in patients with lower‐limb immobilization

Low molecular weight heparin showed no clear difference in mortality due to other causes compared with no prophylaxis or placebo (low certainty).

1 finding from 1 review

Low molecular weight heparin for prevention of venous thromboembolism in patients with lower‐limb immobilization 2017 · Cochrane Headline outcomes only
OR 0.33 [0.01, 8.15]
8 studies · 3111 participants
Low

Low molecular weight heparin vs placebo or no prophylaxis

Mortality due to pulmonary embolism · prevention of venous thromboembolism in patients with lower‐limb immobilization

1 finding from 1 review

Low molecular weight heparin for prevention of venous thromboembolism in patients with lower‐limb immobilization 2017 · Cochrane Headline outcomes only
no estimate extracted
8 studies · 3111 participants
GRADE not reported

Ultrasound‐assisted catheter‐directed thrombolysis plus standard intravenous heparinisation vs standard intravenous heparinisation

All‐cause mortality(7‐day) · people with intermediate‐risk (submassive) APE

1 finding from 1 review

Catheter‐directed therapies for the treatment of high risk (massive) and intermediate risk (submassive) acute… 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 59 participants
GRADE not reported

Ultrasound‐assisted catheter‐directed thrombolysis plus standard intravenous heparinisation vs standard intravenous heparinisation

All‐cause mortality (90‐day) · people with intermediate‐risk (submassive) APE

It is very uncertain whether ultrasound‐assisted catheter‐directed thrombolysis plus standard… changes all‐cause mortality (90‐day) compared with standard intravenous heparinisation (very low certainty).

1 finding from 1 review

Catheter‐directed therapies for the treatment of high risk (massive) and intermediate risk (submassive) acute… 2022 · Cochrane Headline outcomes only
OR 0.31 [0.01, 7.96]
1 study · 59 participants
Very low

Heparin started before vs after the surgical procedure

All‐cause mortality · people undergoing bariatric surgery

1 finding from 1 review

Pharmacological interventions for preventing venous thromboembolism in people undergoing bariatric surgery 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 100 participants
Very low

Heparin started before vs after the surgical procedure

VTE‐related mortality4 · people undergoing bariatric surgery

1 finding from 1 review

Pharmacological interventions for preventing venous thromboembolism in people undergoing bariatric surgery 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 100 participants
Very low

Unfractionated heparin vs no thromboprophylaxis

1‐year overall mortality · ambulatory cancer patients receiving chemotherapy

Unfractionated heparin showed no clear difference in 1‐year overall mortality compared with no thromboprophylaxis (moderate certainty).

1 finding from 1 review

Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
RR 0.86 [0.72, 1.03]
1 study · 277 participants
Moderate

Low molecular weight heparin vs control

Death during study period · children with a CVC

1 finding from 1 review

Low molecular weight heparin for prevention of central venous catheter‐related thrombosis in children 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 813 participants
Low

Low molecular weight heparin vs no prophylaxis

All‐cause mortality ( · adults undergoing KA

1 finding from 1 review

Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy 2022 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 1978 participants
GRADE not reported